Hp1-1 as a Genetic Marker Regulating Inflammation and the Possibility of Developing Diabetic Complications in Patients with Type 2 Diabetes—Cohort Studies
Background: This study assessed the influence of the haptoglobin phenotype on markers regulating inflammation in patients with type 2 diabetes. Methods: The haptoglobin phenotypes, soluble form of CD163 receptor (sCD163), p53 concentrations and high mobility group box protein 1 (HMGB1), interleukin...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | Genes |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4425/11/11/1253 |
| _version_ | 1797549904004907008 |
|---|---|
| author | Anna Stempkowska Magdalena Walicka Edward Franek Marek Naruszewicz Mariusz Panczyk Yaroslav Sanchak Agnieszka Filipek |
| author_facet | Anna Stempkowska Magdalena Walicka Edward Franek Marek Naruszewicz Mariusz Panczyk Yaroslav Sanchak Agnieszka Filipek |
| author_sort | Anna Stempkowska |
| collection | DOAJ |
| description | Background: This study assessed the influence of the haptoglobin phenotype on markers regulating inflammation in patients with type 2 diabetes. Methods: The haptoglobin phenotypes, soluble form of CD163 receptor (sCD163), p53 concentrations and high mobility group box protein 1 (HMGB1), interleukin 10 (IL-10) secretion in serum were assayed via ELISA tests. In the first part of the project, patients were divided into three groups which differed by the haptoglobin phenotype, and afterwards into two groups according to the criterion of the presence or absence of cardiovascular disease. Results: Diabetic patients with haptoglobin phenotype 1-1 (Hp1-1) had a significantly higher concentration of IL-10 and sCD163 compared to haptoglobin phenotype 2-1 (Hp2-1) and haptoglobin phenotype 2-2 (Hp2-2). Moreover, diabetic patients with Hp1-1 had a significantly lower concentration of p53 and HMGB1 compared to diabetic patients with Hp2-1 and Hp2-2. The results have shown that diabetics with Hp2-1 had a significantly lower postprandial glucose level compared to diabetics with Hp2-2. Apart from that, there were no differences in the occurrence of haptoglobin variants between patients with or without cardiovascular disease. Conclusions: Our study provides new data for a relationship between the type of haptoglobin in patients with type 2 diabetes and the concentration of factors that regulate the body’s inflammation. We have shown that the Hp1-1 can serve as a genetic marker of inflammatory processes. |
| first_indexed | 2024-03-10T15:22:01Z |
| format | Article |
| id | doaj.art-bbbb3d5bc19241b490f85392e37645fc |
| institution | Directory Open Access Journal |
| issn | 2073-4425 |
| language | English |
| last_indexed | 2024-03-10T15:22:01Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Genes |
| spelling | doaj.art-bbbb3d5bc19241b490f85392e37645fc2023-11-20T18:26:02ZengMDPI AGGenes2073-44252020-10-011111125310.3390/genes11111253Hp1-1 as a Genetic Marker Regulating Inflammation and the Possibility of Developing Diabetic Complications in Patients with Type 2 Diabetes—Cohort StudiesAnna Stempkowska0Magdalena Walicka1Edward Franek2Marek Naruszewicz3Mariusz Panczyk4Yaroslav Sanchak5Agnieszka Filipek6Clinical Department of Internal Diseases, Endocrinology and Diabetology, Central Clinical Hospital of the MSWiA in Warsaw, Wołoska 137, 02-507 Warsaw, PolandClinical Department of Internal Diseases, Endocrinology and Diabetology, Central Clinical Hospital of the MSWiA in Warsaw, Wołoska 137, 02-507 Warsaw, PolandClinical Department of Internal Diseases, Endocrinology and Diabetology, Central Clinical Hospital of the MSWiA in Warsaw, Wołoska 137, 02-507 Warsaw, PolandDepartment of Pharmacognosy and Molecular Basis of Phytotherapy, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, PolandDepartment of Education and Research in Health Sciences, Faculty of Health Sciences, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, PolandClinical Department of Internal Diseases, Endocrinology and Diabetology, Central Clinical Hospital of the MSWiA in Warsaw, Wołoska 137, 02-507 Warsaw, PolandDepartment of Pharmacognosy and Molecular Basis of Phytotherapy, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, PolandBackground: This study assessed the influence of the haptoglobin phenotype on markers regulating inflammation in patients with type 2 diabetes. Methods: The haptoglobin phenotypes, soluble form of CD163 receptor (sCD163), p53 concentrations and high mobility group box protein 1 (HMGB1), interleukin 10 (IL-10) secretion in serum were assayed via ELISA tests. In the first part of the project, patients were divided into three groups which differed by the haptoglobin phenotype, and afterwards into two groups according to the criterion of the presence or absence of cardiovascular disease. Results: Diabetic patients with haptoglobin phenotype 1-1 (Hp1-1) had a significantly higher concentration of IL-10 and sCD163 compared to haptoglobin phenotype 2-1 (Hp2-1) and haptoglobin phenotype 2-2 (Hp2-2). Moreover, diabetic patients with Hp1-1 had a significantly lower concentration of p53 and HMGB1 compared to diabetic patients with Hp2-1 and Hp2-2. The results have shown that diabetics with Hp2-1 had a significantly lower postprandial glucose level compared to diabetics with Hp2-2. Apart from that, there were no differences in the occurrence of haptoglobin variants between patients with or without cardiovascular disease. Conclusions: Our study provides new data for a relationship between the type of haptoglobin in patients with type 2 diabetes and the concentration of factors that regulate the body’s inflammation. We have shown that the Hp1-1 can serve as a genetic marker of inflammatory processes.https://www.mdpi.com/2073-4425/11/11/1253haptoglobin phenotypesinflammatory markerstype 2 diabetescardiovascular disease |
| spellingShingle | Anna Stempkowska Magdalena Walicka Edward Franek Marek Naruszewicz Mariusz Panczyk Yaroslav Sanchak Agnieszka Filipek Hp1-1 as a Genetic Marker Regulating Inflammation and the Possibility of Developing Diabetic Complications in Patients with Type 2 Diabetes—Cohort Studies Genes haptoglobin phenotypes inflammatory markers type 2 diabetes cardiovascular disease |
| title | Hp1-1 as a Genetic Marker Regulating Inflammation and the Possibility of Developing Diabetic Complications in Patients with Type 2 Diabetes—Cohort Studies |
| title_full | Hp1-1 as a Genetic Marker Regulating Inflammation and the Possibility of Developing Diabetic Complications in Patients with Type 2 Diabetes—Cohort Studies |
| title_fullStr | Hp1-1 as a Genetic Marker Regulating Inflammation and the Possibility of Developing Diabetic Complications in Patients with Type 2 Diabetes—Cohort Studies |
| title_full_unstemmed | Hp1-1 as a Genetic Marker Regulating Inflammation and the Possibility of Developing Diabetic Complications in Patients with Type 2 Diabetes—Cohort Studies |
| title_short | Hp1-1 as a Genetic Marker Regulating Inflammation and the Possibility of Developing Diabetic Complications in Patients with Type 2 Diabetes—Cohort Studies |
| title_sort | hp1 1 as a genetic marker regulating inflammation and the possibility of developing diabetic complications in patients with type 2 diabetes cohort studies |
| topic | haptoglobin phenotypes inflammatory markers type 2 diabetes cardiovascular disease |
| url | https://www.mdpi.com/2073-4425/11/11/1253 |
| work_keys_str_mv | AT annastempkowska hp11asageneticmarkerregulatinginflammationandthepossibilityofdevelopingdiabeticcomplicationsinpatientswithtype2diabetescohortstudies AT magdalenawalicka hp11asageneticmarkerregulatinginflammationandthepossibilityofdevelopingdiabeticcomplicationsinpatientswithtype2diabetescohortstudies AT edwardfranek hp11asageneticmarkerregulatinginflammationandthepossibilityofdevelopingdiabeticcomplicationsinpatientswithtype2diabetescohortstudies AT mareknaruszewicz hp11asageneticmarkerregulatinginflammationandthepossibilityofdevelopingdiabeticcomplicationsinpatientswithtype2diabetescohortstudies AT mariuszpanczyk hp11asageneticmarkerregulatinginflammationandthepossibilityofdevelopingdiabeticcomplicationsinpatientswithtype2diabetescohortstudies AT yaroslavsanchak hp11asageneticmarkerregulatinginflammationandthepossibilityofdevelopingdiabeticcomplicationsinpatientswithtype2diabetescohortstudies AT agnieszkafilipek hp11asageneticmarkerregulatinginflammationandthepossibilityofdevelopingdiabeticcomplicationsinpatientswithtype2diabetescohortstudies |